Combination radiation, immunotherapy, and targeted therapy for liver cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a new combination for liver cancer that cannot be surgically removed yet. It uses tiny radioactive beads (yttrium-90) to deliver radiation directly to the tumor, along with immunotherapy drugs and a targeted therapy to shrink the tumor, with the hope that it can later be surgically removed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a diagnosis of hepatocellular carcinoma (liver cancer) that cannot be removed with surgery right now, but might be removable after treatment.
- Your tumor is only in one lobe of the liver, with no spread to other organs.
- Your liver function is good (Child-Pugh A) and you have a performance status of 0 or 1, meaning you are fully active or only limited in strenuous activity.
- You have not had previous treatments like embolization, targeted therapy, immunotherapy, or radiation for this cancer.
- You are not pregnant (if applicable), and you are willing to use contraception during the study and for 8 weeks after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (atezolizumab and bevacizumab) plus a targeted radiation treatment (Y-90 radioembolization) for people with liver cancer who are waiting for a liver transplant. The goal is to see if this treatment can help control the cancer and improve transplant outcomes.
This trial tests a combination of radiation therapy with two drugs (QL1706 and bevacizumab) for people with liver cancer that hasn't spread to other parts of the body but can't be surgically removed. The goal is to see if this approach can shrink or control the tumor.
This trial tests a combination of two treatments for advanced liver cancer that cannot be removed by surgery. One treatment delivers chemotherapy directly to the tumor, and the other uses tiny beads to block the tumor's blood supply. This approach may help shrink tumors and slow the cancer's growth.
This trial tests a combination of liver-directed treatments and immunotherapy with a targeted drug for people whose liver cancer has spread to a few other organs. It aims to shrink tumors and improve outcomes.
This trial tests adding two immunotherapy and anti-angiogenesis drugs (atezolizumab and bevacizumab) to standard photon radiation for people with liver cancer that cannot be surgically removed. It aims to see if this combination can shrink tumors and improve outcomes.
This trial tests a combination of two immunotherapy drugs (atezolizumab and bevacizumab) with or without targeted radiation therapy for liver cancer that has invaded the major blood vessels of the liver. The goal is to see if adding radiation helps shrink tumors or slow the disease.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.